Modality
Multispecific
MOA
CAR-T BCMA
Target
C5
Pathway
Hedgehog
Atopic DermMDD
Development Pipeline
Preclinical
Aug 2017
→ Sep 2030
PreclinicalCurrent
NCT08969184
1,651 pts·MDD
2017-08→2030-09·Completed
1,651 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-104.4y awayInterim· MDD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2030-09-10 · 4.4y away
MDD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08969184 | Preclinical | MDD | Completed | 1651 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |